---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000123"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:29:53.215768+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials

## Summary
- Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.
- BP1001-A Phase 1/1b solid tumors advanced to second dose cohort; one patient had 15% tumor reduction after 9 cycles; second/third cohorts expected to complete 2025.
- BP1002 Phase 1/1b relapsed/refractory AML: third dose cohort (60 mg/m2) enrollment closed faster than expected; no dose limiting toxicities.
- New preclinical program: BP1001-A for obesity in Type 2 diabetes; expects to file IND in 2025 after completing preclinical testing.
- Patent portfolio includes 7 US patents, 61 foreign patents, and multiple applications pending worldwide.

## SEC filing metadata
- accession: 0001558370-25-000123
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/0001558370-25-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837025000123/bpth-20250110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000123
- JSON: https://secwatch.observer/filing/0001558370-25-000123.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.